S-ONE TRIO-20 is a fluoropyrimidine-based combination therapy. Tegafur is a prodrug of 5-fluorouracil (5-FU), inhibiting DNA synthesis in tumor cells.
Gimeracil inhibits the degradation of 5-FU, increasing its plasma concentration and enhancing antitumor activity.
Oteracil reduces gastrointestinal toxicity by limiting 5-FU activation in the digestive tract.
The tegafur/gimeracil/oteracil combination (S-1) has been evaluated in multiple Phase III clinical trials in gastric and colorectal cancer.
Studies demonstrated comparable or superior efficacy versus intravenous 5-FU, with improved convenience and manageable safety profile. The inclusion of oteracil significantly reduces gastrointestinal adverse reactions.
S-1 is incorporated into international oncology treatment guidelines in several countries.
The medication exerts cytotoxic effects by inhibiting DNA and RNA synthesis in rapidly dividing cancer cells.
The capsules are taken orally after meals with sufficient water. Dosage and treatment schedule are determined individually based on body surface area and clinical protocol. Dose adjustments must only be made by a qualified oncologist.
Contraindications
Side effects
